As a first step, we set forth to verify that the observed reduction in CCL19 and CCL21 in healthy mice was also present in B16F10-Luc tumor-bearing mice treated with the treatment regimens used throughout this study (“TM IR + ICI”, “TM + C-DLN IR + ICI” and “TM + NEO-DLN IR + ICI”) (Fig. 10A). The gene discussed is CCL19; the disease is neoplasm.